Patent ID: 11872249
Assignee: NOVARTIS AG
Field: Pharmaceuticals (Chemistry)
Classification: CPC A  C | IPC A  C

Claim 10:
11. The method of claim 1, wherein the CD20 binding domain comprises a light chain variable region (VL) and a heavy chain variable region (VH), wherein:
(i) the VL comprises the amino acid sequence of SEQ ID NO: 156, 129, 439, 237, 264, 291, 318, or 443, or an amino acid sequence with 95% identity thereto;
(ii) the VH comprises the amino acid sequence of SEQ ID NO: 145, 118, 437, 226, 253, 280, 307, or 441, or an amino acid sequence with at least 95% identity thereto; or
(iii) the VL and VH comprise:
(a) SEQ ID NOs: 156 and 145, respectively;
(b) SEQ ID NOs: 129 and 118, respectively;
(c) SEQ ID NOs: 439 and 437, respectively;
(d) SEQ ID NOs: 237 and 226, respectively;
(e) SEQ ID NOs: 264 and 253, respectively;
(f) SEQ ID NOs: 291 and 280, respectively;
(g) SEQ ID NOs: 318 and 307, respectively; or
(h) SEQ ID NOs: 443 and 441, respectively.